Intra-Coronary Administration of Tacrolimus Improves Myocardial Perfusion and Left Ventricular Function in Patients with ST-Segment Elevation Myocardial Infarction (COAT-STEMI) Undergoing Primary Percutaneous Coronary Intervention.
Left ventricular systolic and diastolic function
Microcirculation
Myocardial perfusion
ST-segment elevation myocardial infarction
Tacrolimus
Journal
Acta Cardiologica Sinica
ISSN: 1011-6842
Titre abrégé: Acta Cardiol Sin
Pays: China (Republic : 1949- )
ID NLM: 101687085
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
entrez:
12
5
2021
pubmed:
13
5
2021
medline:
13
5
2021
Statut:
ppublish
Résumé
Ischemia-reperfusion injury following acute ST-segment elevation myocardial infarction (STEMI) is strongly related to inflammation. However, whether intracoronary (IC) tacrolimus, an immunosuppressant, can improve myocardial perfusion is uncertain. A multicenter double-blind randomized controlled trial was conducted in Taiwan from 2014 to 2017. Among 316 STEMI patients with Killip class ≤ 3 undergoing primary percutaneous coronary intervention (PCI), 151 were assigned to the study group treated with IC tacrolimus 2.5 mg to the culprit vessel before first balloon inflation, and the remaining 165 were assigned to the placebo group receiving IC saline only. The primary endpoint was percentage of post-PCI TIMI-3 flow. The primary composite endpoints included achievement of TIMI-3 flow, TIMI- myocardial perfusion (TMP) grade, or 90-min ST-segment resolution (STR). The secondary endpoints were left ventricular ejection fraction (LVEF) and 1-month/1-year major adverse cardio-cerebral vascular events (MACCEs) (defined as death, myocardial infarction, stroke, target-vessel revascularization or re-hospitalization for heart failure). Although post-PCI TIMI-3 epicardial flow and MACCE rate at 1 month and 1 year did not differ between the two groups, TMP grade (2.54 vs. 2.23, p < 0.001) and 90-min STR (67% vs. 61%, p < 0.001) were significantly higher in the tacrolimus-treated group than in the placebo group. The STEMI patients treated with tacrolimus also had significantly higher 3D LVEF and less grade 2 or 3 LV diastolic dysfunction at 9 months compared to those without. IC tacrolimus for STEMI improved coronary microcirculation and 9-month LV systolic and diastolic functions. However, the benefit of tacrolimus on clinical outcomes remains inconclusive due to insufficient patient enrollment.
Sections du résumé
BACKGROUND
BACKGROUND
Ischemia-reperfusion injury following acute ST-segment elevation myocardial infarction (STEMI) is strongly related to inflammation. However, whether intracoronary (IC) tacrolimus, an immunosuppressant, can improve myocardial perfusion is uncertain.
METHODS
METHODS
A multicenter double-blind randomized controlled trial was conducted in Taiwan from 2014 to 2017. Among 316 STEMI patients with Killip class ≤ 3 undergoing primary percutaneous coronary intervention (PCI), 151 were assigned to the study group treated with IC tacrolimus 2.5 mg to the culprit vessel before first balloon inflation, and the remaining 165 were assigned to the placebo group receiving IC saline only. The primary endpoint was percentage of post-PCI TIMI-3 flow. The primary composite endpoints included achievement of TIMI-3 flow, TIMI- myocardial perfusion (TMP) grade, or 90-min ST-segment resolution (STR). The secondary endpoints were left ventricular ejection fraction (LVEF) and 1-month/1-year major adverse cardio-cerebral vascular events (MACCEs) (defined as death, myocardial infarction, stroke, target-vessel revascularization or re-hospitalization for heart failure).
RESULTS
RESULTS
Although post-PCI TIMI-3 epicardial flow and MACCE rate at 1 month and 1 year did not differ between the two groups, TMP grade (2.54 vs. 2.23, p < 0.001) and 90-min STR (67% vs. 61%, p < 0.001) were significantly higher in the tacrolimus-treated group than in the placebo group. The STEMI patients treated with tacrolimus also had significantly higher 3D LVEF and less grade 2 or 3 LV diastolic dysfunction at 9 months compared to those without.
CONCLUSIONS
CONCLUSIONS
IC tacrolimus for STEMI improved coronary microcirculation and 9-month LV systolic and diastolic functions. However, the benefit of tacrolimus on clinical outcomes remains inconclusive due to insufficient patient enrollment.
Identifiants
pubmed: 33976507
doi: 10.6515/ACS.202105_37(3).20201025C
pmc: PMC8107710
doi:
Types de publication
Journal Article
Langues
eng
Pagination
239-253Références
Eur J Echocardiogr. 2011 May;12(5):339-53
pubmed: 21555455
J Mol Cell Cardiol. 2007 Jan;42(1):150-8
pubmed: 17070837
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
N Engl J Med. 1992 Sep 3;327(10):669-77
pubmed: 1386652
Chest. 2002 Oct;122(4):1322-32
pubmed: 12377860
J Am Coll Cardiol. 1994 Aug;24(2):384-91
pubmed: 8034872
Eur Heart J Acute Cardiovasc Care. 2012 Sep;1(3):210-21
pubmed: 24062909
Circulation. 1996 Jan 15;93(2):223-8
pubmed: 8548892
Am J Cardiol. 2003 Dec 1;92(11):1331-5
pubmed: 14636915
Int J Cardiol. 2005 Apr 20;100(2):179-90
pubmed: 15823623
N Engl J Med. 2007 Sep 13;357(11):1121-35
pubmed: 17855673
Nephrol Dial Transplant. 2003 May;18 Suppl 1:i7-11
pubmed: 12738757
J Atheroscler Thromb. 2013;20(1):9-22
pubmed: 22972310
N Engl J Med. 2019 Dec 26;381(26):2497-2505
pubmed: 31733140
J Inflamm (Lond). 2012 Jun 01;9(1):21
pubmed: 22658082
Am J Cardiol. 2000 Mar 9;85(5A):50B-60B
pubmed: 11076131
Int J Cardiol. 2011 Feb 17;147(1):79-87
pubmed: 19751953
J Am Coll Cardiol. 2012 Mar 13;59(11):969-78
pubmed: 22402067
J Clin Invest. 1985 Nov;76(5):1713-9
pubmed: 4056048
J Thorac Cardiovasc Surg. 2008 Jan;135(1):123-30, 130.e1-2
pubmed: 18179928
Am Heart J. 2010 Nov;160(5):842-848.e1-2
pubmed: 21095270
N Engl J Med. 1985 Apr 4;312(14):932-6
pubmed: 4038784
Circulation. 2015 Oct 13;132(15):1395-403
pubmed: 26265659
Circulation. 1998 Jun 16;97(23):2302-6
pubmed: 9639373
Mitochondrion. 2010 Mar;10(2):94-101
pubmed: 19836469
Int Heart J. 2008 Jan;49(1):1-11
pubmed: 18360060
Am J Cardiol. 2001 May 15;87(10):1184-8; A4
pubmed: 11356395
J Am Coll Cardiol. 2013 Jan 29;61(4):e78-e140
pubmed: 23256914
Am Heart J. 2013 Oct;166(4):676-83
pubmed: 24093847
Cardiovasc Res. 2002 Jan;53(1):31-47
pubmed: 11744011
Circulation. 2002 Jan 22;105(3):282-5
pubmed: 11804979
Circ J. 2007 Aug;71(8):1213-8
pubmed: 17652883
J Mol Cell Cardiol. 2000 Dec;32(12):2141-9
pubmed: 11112990
JACC Cardiovasc Interv. 2011 Jun;4(6):599-604
pubmed: 21700244
Ann N Y Acad Sci. 1993 Nov 30;696:9-19
pubmed: 7509138
J Biomed Sci. 2013 Oct 29;20:82
pubmed: 24165293
N Engl J Med. 2015 Sep 10;373(11):1021-31
pubmed: 26321103